Relating in vitro neutralisation level and protection in the CVnCoV (CUREVAC) trial.

Field	Value	Language
dc.contributor.author	Cromer, Deborah	en
dc.contributor.author	Reynaldi, Arnold	en
dc.contributor.author	Steain, Megan	en
dc.contributor.author	Triccas, James A	en
dc.contributor.author	Davenport, Miles P	en
dc.contributor.author	Khoury, David S	en
dc.date.accessioned	2022-04-28T02:45:31Z
dc.date.available	2022-04-28T02:45:31Z
dc.date.issued	2022
dc.identifier.uri	https://hdl.handle.net/2123/28443
dc.description.abstract	The vaccine candidate CVnCoV (CUREVAC) showed surprisingly low efficacy in a recent phase 3 trial compared with other mRNA vaccines. Here we show that the low efficacy follows from the dose used and the presence of SARS-CoV-2 variants, and is predicted by the neutralising antibody response induced by the vaccine.	en
dc.language.iso	en	en
dc.rights	Other
dc.subject	COVID-19	en
dc.subject	Coronavirus	en
dc.title	Relating in vitro neutralisation level and protection in the CVnCoV (CUREVAC) trial.	en
dc.type	Article	en
dc.identifier.doi	10.1093/cid/ciac075
usyd.faculty	Faculty of Medicine and Health, School of Medical Sciences	en

Associated file/s

There are no files associated with this item.